Navigation Links
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Date:5/26/2009

tial drug candidates have arisen from research activities that are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drug candidates directed at treatments for cardiovascular disease, cancer and other diseases. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

Forward-Looking Statements: Amgen

This news release contains forward-looking statements that are based on Amgen's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to Amgen's business. Unless otherwise noted, Amgen is providing this information as of May 26, 2009, and expressly disclaims any duty to update information contained in this news release.

No forward-loo
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Protocol Assessment with the Food and Drug ... - AEterna Zentaris Inc. (NASDAQ: AEZS ... biopharmaceutical company focused on oncology and endocrine ... partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), ... for perifosine (KRX-0401), the Company,s PI3K/Akt pathway ...
(Date:12/15/2009)... -- Epeius Biotechnologies Corporation, an emerging leader in ... validation of the cutting-edge science behind its lead ... the world rediscovered the Cyclin G1 gene ... pathogenesis and disease progression, and thus a prime ... NIH National Cancer Institute investigating the role of ...
(Date:12/15/2009)... DIEGO, Dec. 15 Aethlon Medical, Inc. ... Dr. Jeff Schorey and Dr. Wayne Comper ... Exosome Sciences, Inc. (ESI). Both Dr. Schorey and ... field. ESI, a wholly owned subsidiary of Aethlon ... that the Hemopurifier®, a medical device being advanced ...
(Date:12/15/2009)... -- The Center for Business Intelligence (CBI), ... to announce the full agenda for the ... Congress . The forum will take place ... 2010. ,, Over 1,500 senior-level Finance, Accounting, ... premier event since its inception, and this ...
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2
... Adrian R. Elliott, Peer M. Schenk and Christopher P.L. Grof , ... , Introduction , ... is a useful , reporter gene in higher ... emitted is easy to detect and requires no substrate or cofactors. Furthermore, , ...
... Julie Chang, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel Drive,Hercules, CA 94547, ... , Capillary sequencing technology has altered ... and automating the sequencing process. This high-throughput , ... achievements as the completion of the Human Genome Project. ...
... Pullinger, Arghavan K. Shahidi, Andrea L. Verhagen and John , ... * Department of Medicine, Department , of ... California , , ... of fields, techniques are required for searching candidate , ...
Other Biology Technology:Quantitative Analysis of GFP in Plant Extracts Using the VersaFluor Fluorometer System 2Quantitative Analysis of GFP in Plant Extracts Using the VersaFluor Fluorometer System 3Comparison of Commercial Dye Terminator Removal Kits, Rev A 2Comparison of Commercial Dye Terminator Removal Kits, Rev A 3Comparison of Commercial Dye Terminator Removal Kits, Rev A 4Comparison of Commercial Dye Terminator Removal Kits, Rev A 5Detection of Apolipoprotein Gene Variants by DGGE Using the DCode System 2Detection of Apolipoprotein Gene Variants by DGGE Using the DCode System 3Detection of Apolipoprotein Gene Variants by DGGE Using the DCode System 4
(Date:12/16/2009)... pesticides in rivers and basins may limit the ... addition to the widespread deterioration of salmon habitats, ... pesticides may further inhibit the recovery of threatened ... currently underway to restore Pacific salmon habitats in ... Baldwin of the National Oceanic and Atmospheric Administration ...
(Date:12/16/2009)... December 15, 2009 Signal Hill, CA Tom ... public and president of Bowman Global Change, has developed ... the fourth Intergovernmental Panel on Climate Change (IPCC) report ... to the authentic scientific information they need to make ... Bowman created the new format as a means to ...
(Date:12/16/2009)... a global provider of business process outsourcing (BPO) services, ... Awards Top 100 IT project of 2009 for its ... for iQor. ,, "We are honored to be recognized ... president and CEO of iQor. "TeQ21 is completely transforming ... faster, smarter and with the added security biometrics provides. ...
Breaking Biology News(10 mins):Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2Bowman creates graphic translation of climate change data 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Optimer Pharmaceuticals to Present at the 28th Annual J P Morgan Healthcare Conference 7037 1Optimer Pharmaceuticals to Present at the 28th Annual J P Morgan Healthcare Conference 7037 2Pros and Cons of Electronic Medical Records Weighed 63381 1Pros and Cons of Electronic Medical Records Weighed 63381 2Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247 com 63377 1Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247 com 63377 2Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247 com 63377 3Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247 com 63377 4
... a mixture of two different kinds of cells have in ... basic force causes both mixtures to separate into two distinct ... computer model of the cell sorting process produced by Shane ... colleagues at the University of Waterloo in Canada that is ...
... using nanotechnology to search for new cancer-fighting drugs through ... faster than current methods. , The "Lab-on-Bead" process will ... so small that 1,000 of them would fit across ... chemical, which can be identified later if it displays ...
... Brazilian palm berry, popular health food though little research has ... better understood. , In the first research involving people, the ... in the human body when consumed both as juice and ... scientists, was published in a recent issue of the ...
Other Biology News:Surface tension drives segregation within cell mixtures 2Nanoscopic screening process to speed drug discovery 2Research shows Brazilian acai berry antioxidants absorbed by human body 2Research shows Brazilian acai berry antioxidants absorbed by human body 3
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Prostaglandin-E2 receptor EP2/EP3 Market Segment: GPCRs...
... Product Goat polyclonal to BRF2 Immunogen ... amino acids 406-419 of Human BRF2. Reactivity ... tested in other species. Background Information ... the RNA polymerase III transcription factor complex required ...
... Antibody - Red, 20X ... antibody at 20X concentration for use ... assays. Quality Assurance ... FarRed fluorescence polarization assays. ...
Biology Products: